About Theratechnologies. com. Betteryear2. com uses cookies on this site. com uses cookies on this site. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Aug. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. See a list of the most recent Stock Forum posts on Stockhouse. 1-438. . By continuing to use our service, you agree to our use of cookies. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. 2. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Theratechnologies Inc. 25. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. We also use them to share usage information with our partners. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. com uses cookies on this site. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. Paul Levesque - President. During the last trading day the stock fluctuated 12. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 54% and a negative trailing twelve-month return on equity of 1,116. By continuing to use our service, you agree to our use of cookies. TH | July 20, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. -986. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. R. We also use them to share usage. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 5%. Theratechnologies Inc. Stockhouse. sBLA for F8 formulation of tesamorelin submitted to FDA. US Headquarters. Real-time discussion about Theratechnologies Inc. com uses cookies on this site. Biopharmaceutical company Theratechnologies Inc. MONTREAL, Feb. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. 514-336-7800. MONTREAL, Sept. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Investor Relations. org. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 9 million and US$19. By continuing to use our service, you agree to our use of cookies. 29(+0. Theratechnologies inc. Theratechnologies. -4. MONTREAL, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Saint-Laurent, Canada. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. 66% compared to the previous year's 69. ET. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. 81 million for the quarter. By continuing to use our service, you agree to our use of cookies. 51 S1. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. Apr 14, 2020, 8:30 a. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. - 2023 Q3 positive adjusted EBITDA to be. Stockhouse. MONTREAL, Oct. . (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. com. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. 46. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. We currently market prescription products for people with HIV in the United States. Remember, high Theratechnologies' alpha is almost always a sign of. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. (TH. 54% and a negative trailing twelve-month return on equity of. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. 03) EPS for the quarter, beating the consensus estimate of ($0. Shares of Theratechnologies are up 4. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Theratechnologies reduces R&D head count to compensate for sales setback. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. S. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. Montréal, Québec, Canada . Proceeds to Be Used to Redeem All of the Outstanding 5. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. Theratechnologies Appoints New Board Member. P. T. This news release constitutes a “designated news release” for the purposes of the Company’s. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Further. : Nasdaq Theratechnologies Inc. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. About TH1902. The Theratechnologies Inc. NCU. Theratechnologies Provides Details About R&D Day Webcast. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. GlobeNewswire. European Headquarters. stock price gained 1. : 001-35203 Mr. 4% from the stock's current price. FY2023 revenue guidance range set between $90 million and $95 million. About SORT1+ Technology™ and TH1902. By continuing to use our service, you agree to our use of cookies. MONTREAL, Jan. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Further. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces 1-for-4 Reverse Stock Split. There are 102 news items for this page. THTX earnings call for the period ending February 29, 2020. com. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage information with our partners. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. com uses cookies on this site. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. : Renegotiated Lease to Generate Substantial Annual Savings. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. THERATECHNOLOGIES INC. 08 (+6. 5% workforce reduction. This news release constitutes a “designated news release” for the purposes. S. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. Theratechnologies Stock Price, News and Company Updates. Theratechnologies had a negative net margin of 36. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. Watch list NEW Set a price target alert After Hours Last. . By continuing to use our service, you agree to our use of cookies. com. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. MONTREAL, Dec. Cookies are used to offer you a better browsing experience and to analyze our traffic. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. It's a different kind of fat that may require a different type of treatment. (THTX) Stock Price, Quote & News - Stock Analysis -20. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. com uses cookies on this site. MONTREAL, Nov. Data presented at AMCP Nexus 2023. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Unveiling Silvercorp's golden potential at the Ying Mining District. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00 to $36. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Last Reviewed: February 24, 2023. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. com uses cookies on this site. Stockhouse. (882) posted 3 minutes ago. Senior Director, Communications & Corporate Affairs. View real-time stock prices and stock quotes for a full financial overview. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. We also use them to share usage. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. 40%. Headquarters. 74M. S. Clinical-stage pharmaceutical company Theralase Technologies Inc. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. October 13, 2022 07:30 ET | Source: Theratechnologies. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. is an employee of TaiMed Biologics USA, Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. Stockhouse. THERATECHNOLOGIES INC. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. By continuing to use our service, you agree to our use of cookies. Stockhouse. 74M. stock news by MarketWatch. Phone Number (514) 336-7800. 20% from a day low at $1. 72%. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 4. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. THERATECHNOLOGIES INC. Stockhouse. 1-514-336-7800. Currency in USD Follow 2W 10W 9M 1. GlobeNewswire. By continuing to use our service, you agree to our use of cookies. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. About Us | Theratechnologies Inc. 71%. The firm offers its product under the brand name of. View real-time stock prices and stock quotes for a full financial overview. Cookies are used to offer you a better browsing experience and to analyze our traffic. Q4 2022 consolidated revenue growth of 14. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. S. Theratechnologies inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. Theratechnologies Inc. Stockhouse. A high-level overview of Theratechnologies Inc. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. com uses cookies on this site. Share your ideas and get valuable. Stockhouse. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. This news release constitutes a "designated news release" for the purposes of. Montréal, Québec, Canada . The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. 75%. MONTREAL, Oct. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Northwest also announces an update on its. 3. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. View real-time stock prices and stock quotes for a full financial overview. Browse posts by Sector and Subsector. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com 10/16/2023. Track Theratechnologies Inc. ASP | Complete Acerus Pharmaceuticals Corp. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. We also use them to share usage. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. com uses cookies on this site. Theratechnologies Inc. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. Theratechnologies to Announce Financial Results for Its First Quarter 2022. Find the latest Theratechnologies Inc. 4 million. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Marsolais will present at the H. Thank you. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. stock news by MarketWatch. This module allows you to check different measures of market premium (i. Theratechnologies, Inc. 81 million for the quarter. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. 9 million as at August 31, 2023. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Stockhouse. (2013-04-03 | TSX:TH) Theratechnologies Inc. (882) posted 3 minutes ago. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2013-04-03 | TSX:TH) Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. com uses cookies on this site. Theratechnologies Appoints New Board Member. MONTREAL, Nov. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Trogarzo® and. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. FAQ – Utilisateurs de TMX Argent NOUVEAU. Jours fériés des marchés. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). TH | September 5, 2023. T. US Headquarters. TH | February 28, 2023. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. acts as investment manager. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. 65 per cent to C$1. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 617-356-1009. By continuing to use our service, you agree to our use of cookies. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. Gary Littlejohn Stockhouse. By continuing to use our service, you agree to our use of cookies. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. 's motion for leave to commence. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. 86%. Stockhouse. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 89 52. Stockhouse. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 17. Stockhouse. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. . The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. $44. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | July 20, 2023. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Investor Relations. Theratechnologies, Inc. Christian Marsolais, Ph. Cookies are used to offer you a better browsing experience and to analyze our traffic. A high-level overview of Theratechnologies Inc. 89 $2. 2% per year. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. , alpha and beta) for all equities such as Theratechnologies. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. T. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. In the United States, Trogarzo ® (ibalizumab. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. com uses cookies on this site. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. com. By continuing to use our service, you agree to our use of cookies. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. MONTREAL, Nov. .